Library Subscription: Guest
Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections
Critical Reviews™ in Therapeutic Drug Carrier Systems
IF: 2.9 5-Year IF: 3.72 SJR: 0.736 SNIP: 0.818 CiteScore™: 4.6

ISSN Print: 0743-4863
ISSN Online: 2162-660X

Volumes:
Volume 37, 2020 Volume 36, 2019 Volume 35, 2018 Volume 34, 2017 Volume 33, 2016 Volume 32, 2015 Volume 31, 2014 Volume 30, 2013 Volume 29, 2012 Volume 28, 2011 Volume 27, 2010 Volume 26, 2009 Volume 25, 2008 Volume 24, 2007 Volume 23, 2006 Volume 22, 2005 Volume 21, 2004 Volume 20, 2003 Volume 19, 2002 Volume 18, 2001 Volume 17, 2000 Volume 16, 1999 Volume 15, 1998 Volume 14, 1997 Volume 13, 1996 Volume 12, 1995

Critical Reviews™ in Therapeutic Drug Carrier Systems

DOI: 10.1615/CritRevTherDrugCarrierSyst.v22.i5.20
pages 465-492

Pharmacogenomics and Its Potential Impact on Drug and Formulation Development

Karin Regnstrom
Department of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, Storrs, Connecticut, USA
Diane J. Burgess
Professor, Department of Pharmaceutical Sciences, School of Pharmacy, University of Connecticut, Storrs, Connecticut, USA

ABSTRACT

Recent advances in genomic research have provided the basis for new insights into the importance of genetic and genomic markers during the different stages of drug development. A new field of research, pharmacogenomics, which studies the relationship between drug effects and the genome, has emerged. Structural pharmacogenomics maps the complete DNA sequences of whole genomes (genotypes) including individual variations, and functional pharmacogenomics assesses the expression levels of thousands of genes in one single experiment. Together, these two areas of pharmacogenomics have generated massive databases, which have become a challenge for the research field of informatics and have fostered a new branch of research, bioinformatics. If skillfully used, the databases generated by pharmacogenomics together with data mining on the Web promise to improve the drug development process in a variety of areas: identification of drug targets, evaluation of toxicity, classification of diseases, evaluation of formulations, assessment of drug response and treatment, post-marketing applications, and development of personalized medicines.


Articles with similar content:

Toward Focused Ultrasound Liver Surgery under Free Breathing
Critical Reviews™ in Biomedical Engineering, Vol.40, 2012, issue 3
Tobias Preusser, Matthias Gunther, Stefan Braunewell
siRNA: A Potential Tool for Future Breast Cancer Therapy?
Critical Reviews™ in Oncogenesis, Vol.12, 2006, issue 1-2
Eirik Frengen, Tone Ikdahl Andersen, Charles M. Perou, Gro Leite Storvold
Impact of the Microbiome on the Immune System
Critical Reviews™ in Immunology, Vol.39, 2019, issue 5
Stephen Mathew, Sohail Siraj, Riyaz Basha, Umesh T. Sankpal, Krishna Patel, Christoffer Briggs Lambring
Stealth Engineering for In Vivo Drug Delivery Systems
Critical Reviews™ in Biomedical Engineering, Vol.43, 2015, issue 5-6
Ankita Mohapatra, Richard A. Smith, Bashir I. Morshed, Warren O. Haggard
Structuring Polymers for Delivery of DNA-Based Therapeutics: Updated Insights
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.29, 2012, issue 6
Suresh P. Vyas, Shailja Tiwari, Madhu Gupta